Arvinas, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of therapies to degrade disease-causing proteins using its proprietary PROTAC® protein degradation platform.

Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.Community Guidelines: http://bit.ly/ArvinasCG

ArrowMark Partners

Avidity Partners

BB Biotech Ventures

Great Point Partners

Surveyor Capital

RTW Investments

Boxer Capital

Citadel Global Equities

EcoR1 Capital

RA Capital Management

5AM Ventures

Hillhouse Capital Group

Sirona Capital

Canaan Partners

Deerfield

New Leaf Venture Partners

Nextech Invest

OrbiMed

Arvinas

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

Arvinas, Inc.

COM:ARVINAS

Arvinas, Inc.

Last Close

25.11

22/11 21:00

Market Cap

1.80B

Beta: -

Volume Today

1.04M

Avg: -

Analysis Not Available